Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
Oncoinvent ASA (ONCIN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.103x
Based on the latest financial reports, Oncoinvent ASA (ONCIN) has a cash flow conversion efficiency ratio of -1.103x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-73.90 Million) by net assets (Nkr67.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncoinvent ASA - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncoinvent ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoinvent ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canterbury Resources Ltd
AU:CBY
|
-0.053x |
|
Galilee Energy Ltd
AU:GLL
|
59.704x |
|
Great Western Mining Corp Plc
IR:8GW
|
-0.026x |
|
York Harbour Metals Inc
OTCGREY:YORKF
|
-0.016x |
|
INEO Tech Corp
OTCQB:INEOF
|
0.040x |
|
Emetals Ltd
AU:EMT
|
-0.054x |
|
Mazarin Inc
V:MAZ-H
|
1.069x |
|
Advent Wireless Inc
V:AWI
|
0.030x |
Annual Cash Flow Conversion Efficiency for Oncoinvent ASA (2021–2025)
The table below shows the annual cash flow conversion efficiency of Oncoinvent ASA from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr146.33 Million | Nkr-131.19 Million | -0.897x | +36.62% |
| 2024-12-31 | Nkr108.33 Million | Nkr-153.24 Million | -1.415x | -30.56% |
| 2023-12-31 | Nkr127.48 Million | Nkr-138.11 Million | -1.083x | +66.73% |
| 2022-12-31 | Nkr88.50 Million | Nkr-288.23 Million | -3.257x | -312.75% |
| 2021-12-31 | Nkr384.43 Million | Nkr-303.34 Million | -0.789x | -- |